Roche
Headquarters: Basel, Switzerland.
Strengths: A world-leading giant in the R & D and production of anti-tumor drugs, with important products in the treatment of various cancers. For example, Herceptin (trastuzumab) for breast cancer is the world's first monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2), which has significantly improved the prognosis of HER2-positive breast cancer patients; Rituxan (rituximab) is used for the treatment of hematological malignancies such as lymphoma, opening a new era of immunotherapy for lymphoma.
Novartis
Headquarters: Basel, Switzerland.
Strengths: It has an excellent performance in tumor-targeted therapy drugs. Imatinib (Gleevec), a tyrosine kinase inhibitor developed by it for the treatment of chronic myeloid leukemia, has opened a new era of tumor-targeted therapy; Tasigna (nilotinib) has further optimized the treatment plan for chronic myeloid leukemia.
Merck & Co.
Headquarters: New Jersey, USA.
Strengths: It has achieved remarkable results in the field of tumor immunotherapy. Keytruda (pembrolizumab) developed by it is an anti-PD-1 monoclonal antibody, approved for the treatment of multiple cancers such as melanoma, non-small cell lung cancer, and head and neck squamous cell carcinoma, which has greatly changed the pattern of cancer treatment.
Pfizer
Headquarters: New York, USA.
Strengths: It has a rich product line and has made huge investments in the R & D and production of oncology drugs. For example, Ibrance (palbociclib) is the world's first cyclin-dependent kinase (CDK) 4/6 inhibitor. When used in combination with an aromatase inhibitor, it is used for the treatment of locally advanced or metastatic breast cancer that is hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative.
AstraZeneca
Headquarters: Cambridge, UK.
Strengths: Focusing on the R & D of innovative oncology drugs, it has achieved remarkable results in the field of lung cancer treatment. Tagrisso (osimertinib) is used for the treatment of non-small cell lung cancer and has good efficacy for patients with specific gene mutations; Imfinzi (durvalumab) is an anti-PD-L1 monoclonal antibody that can be used for the treatment of locally advanced or metastatic non-small cell lung cancer, etc.
Eli Lilly and Company
Headquarters: Indianapolis, USA.
Strengths: It has layouts in tumor immunotherapy, targeted therapy, etc. Donafenib, a new drug for Alzheimer's disease developed by it, also has certain applications in the treatment of tumors such as liver cancer. In addition, the sodium valetrocite sulfate tablets developed by Eli Lilly in cooperation with Hutchison MediPharma are also constantly exploring in the treatment of kidney cancer, etc.
Sanofi
Headquarters: Paris, France.
Strengths: It is involved in fields such as hematological tumors and solid tumors. Its drug Jakavi (ruxolitinib) is used for the treatment of hematological diseases such as myelofibrosis and polycythemia vera; Sanofi also continuously expands its oncology drug product line through acquisitions and other means to enhance its competitiveness in the field of tumor treatment.
Bristol-Myers Squibb (BMS)
Headquarters: New York, USA.
Strengths: It has an important position in the field of tumor immunotherapy. Opdivo (nivolumab), developed by it, is the world's first PD-1 inhibitor approved for marketing, which plays an important role in the treatment of multiple cancers such as melanoma, non-small cell lung cancer, and kidney cancer.
Amgen
Headquarters: California, USA.
Strengths: It has strong strength in the R & D and production of oncology biopharmaceuticals, especially in hematopoietic growth factors and drugs for the treatment of tumor bone metastases. For example, Neulasta (pegfilgrastim) is used to reduce the risk of infection caused by cancer chemotherapy; Xgeva (denosumab) is used to prevent bone-related events in patients with solid tumor bone metastases.
AbbVie
Headquarters: Illinois, USA.
Strengths: It has an excellent performance in the treatment of hematological tumors. Venclexta (venetoclax) developed by it is a BCL-2 inhibitor, used for the treatment of hematological malignancies such as chronic lymphocytic leukemia, providing new treatment options for patients.
